Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 1.00 |
| ▸ | CASP7 | P55210 | 15/20 | 1.00 |
| ▸ | CASP9 | P55211 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 6/20 | 0.82 |
| ▸ | CASP2 | P42575 | 3/20 | 0.74 |
| ▸ | CASP6 | P55212 | 3/20 | 0.74 |
| ▸ | CASP4 | P49662 | 2/20 | 0.74 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681388 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL30657493 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL5332434 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535575 | 0.90 | CASP3 (0.81) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535497 | 0.88 | CASP3 (0.82) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535499 | 0.88 | CASP3 (0.82) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL13925543 | 0.88 | CASP3 (0.78) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535139 | 0.87 | CASP3 (0.84) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535137 | 0.87 | CASP3 (0.84) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL2263591 | 0.85 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| US-20200046796-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2020-02-13 | — | — | US | claimed |
| EP-3525791-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | Technion Research & Development Foundation Limited (IL) | 2019-08-21 | — | — | EP | claimed |
| WO-2018069885-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-04-19 | — | — | WO | claimed |
| US-20150190456-A1 | USE OF CASPASE 3 ACTIVITY AND ITS INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2015-07-09 | — | — | US | claimed |
| WO-2012177684-A2 | USE OF CASPASE 3 ACTIVITY AND ITS INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-12-27 | — | — | WO | claimed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | claimed |
| EP-1907003-A2 | COMBINATION THERAPY WITH INHIBITORS OF HMGB AND CASPASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Feinstein Institute for Medical Research (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2006124477-A2 | COMBINATION THERAPY WITH INHIBITORS OF HMGB AND CASPASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | claimed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | claimed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | claimed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | claimed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | HMGB2, HMGB3, HMGB1 | CASP3 61/4885CASP7 39/4885CASP9 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.